1. Buchner T: Treatment of adult acute leukemia. Curr Opin Oncol 9:18, 1997.

2. Germain R: Antigen processing and presentation. In: Paul W (ed.) Fundamental Immunology. 2nd ed. Philadelphia, PA: Lippincott-Raven;1999:287.

3. Lanier LL: NK cell receptors. Annu Rev Immunol 16:359, 1998.

4. The MHC sequencing consortium: Complete sequence and gene map of a human major histocompatibility complex. Nature 401:921, 1999.

5. Mungall AJ, Palmer SA, Sims SK, et al.: The DNA sequence and analysis of human chromosome 6. Nature 425:805, 2003.

6. Klein J, Sato A: The HLA system. First of two parts. N Engl J Med 343:702, 2000.

7. Margulies D: The major histocompatibility complex. In: Paul W (ed.) Fundamental Immunology. 4th ed. Philadelphia, PA: Lippincott-Raven;1999:263.

8. Goodfellow P, Jones E, Van Heyningen V, et al.: The beta2-microglobulin gene is on chromosome 15 and not in the HL-A region. Nature 254:267, 1975.

9. Andersson G, Larhammar D, Widmark E, et al.: Class II genes of the human major histocompatibility complex. Organization and evolutionary relationship of the DR beta genes. J Biol Chem 262:8748, 1987.

10. Gorski J, Rollini P, Mach B: Structural comparison of the genes of two HLA-DR supertypic groups: the loci encoding DRw52 and DRw53 are not truly allelic. Immunogenetics 25:397, 1987.

11. Kawai J, Ando A, Sato T, et al.: Analysis of gene structure and antigen determinants of DR2 antigens using DR gene transfer into mouse L cells. J Immunol 142:312, 1989.

12. Tautz C, Marsh DG, Baur X: A novel HLA-haplotype containing a DRB5 gene not associated with DRB1*15 or DRB1*16 alleles. Tissue Antigens 39:91, 1992.

13. Nesci S, Talevi N, Andreani M, et al.: An unusual DRB1*1503 haplotype without a detectable DRB5 locus in a black African family. Tissue Antigens 49:53, 1997.

14. Robbins F, Hurley CK, Tang T, et al.: Diversity associated with the second expressed HLA-DRB locus in the human population. Immunogenetics 46:104, 1997.

15. Wade JA, Hurley CK, Hastings A, et al.: Combinatorial diversity in DR2 haplotypes. Tissue Antigens 41:113, 1993.

It is important to develop consensus on the effect of mismatching for other HLA loci that have not been well studied or for which there are conflicting indications. Since a significant fraction of patients do not have fully matched donors (related or unrelated), it is important to determine if certain HLA mismatches may be better tolerated than others and produce less risk of adverse outcome. This will require the study of large numbers of patient/donor pairs that have been HLA typed at allele level for each of the polymorphic loci.

16. Sutton VR, Kienzle BK, Knowles RW: An altered splice site is found in the DRB4 gene that is not expressed in HLA-DR7, Dw11 individuals. Immunogenetics 29:317, 1989.

17. Voorter CE, Roeffaers HE, du Toit ED, et al.: The absence of DR51 in a DRB5-positive individual DR2ES is caused by a null allele (DRB5*0108N). Tissue Antigens 50:326, 1997.

18. Balas A, Ocon P, Vicario JL, et al.: HLA-DR51 expression failure caused by a two-base deletion at exon 2 of a DRB5 null allele (DRB5*0110N) in a Spanish gypsy family. Tissue Antigens 55:467, 2000.

19. Saper MA, Bjorkman PJ, Wiley DC: Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol 219:277, 1991.

20. Bjorkman PJ, Saper MA, Samraoui B, et al.: Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506, 1987.

21. Brown JH, Jardetzky TS, Gorga JC, et al.: Three-dimensional structure of the human class II histocompatibil-ity antigen HLA-DR1. Nature 364:33, 1993.

22. Stern LJ, Brown JH, Jardetzky TS, et al.: Crystal structure of the human class II MHC protein HLA-DR1 com-plexed with an influenza virus peptide. Nature 368:215, 1994.

23. Petersdorf EW, Hansen JA, Martin PJ, et al.: Major-his-tocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345: 1794, 2001.

24. Elsner HA, DeLuca D, Strub J, et al.: HistoCheck: rating of HLA class I and II mismatches by an internet-based software tool. Bone Marrow Transplant 33:165, 2004.

25. Garrett TP, Saper MA, Bjorkman PJ, et al.: Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 342:692, 1989.

26. Bjorkman PJ, Saper MA, Samraoui B, et al.: The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329:512, 1987.

27. Hennecke J, Carfi A, Wiley DC: Structure of a cova-lently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. Embo J 19:5611, 2000.

28. Goulmy E, Schipper R, Pool J, et al.: Mismatches of minor histocompatibility antigens between HLA-

identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334:281, 1996.

29. Goulmy E: Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157:125, 1997.

30. Sherman LA, Chattopadhyay S: The molecular basis of allorecognition. Annu Rev Immunol 11:385, 1993.

31. Elliott TJ, Eisen HN: Cytotoxic T lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule. Proc Natl Acad Sci USA 87:5213, 1990.

32. Smith PA, Brunmark A, Jackson MR, et al.: Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J Exp Med 185:1023, 1997.

33. Wang W, Man S, Gulden PH, et al.: Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides.

J Immunol 160:1091, 1998.

34. Kovalik JP, Singh N, Mendiratta SK, et al.: The alloreac-tive and self-restricted CD4+ T cell response directed against a single MHC class Il/peptide combination.

J Immunol 165:1285, 2000.

35. Rotzschke O, Falk K, Faath S, et al.: On the nature of peptides involved in T cell alloreactivity. J Exp Med 174:1059, 1991.

36. Chattopadhyay S, Theobald M, Biggs J, et al.: Conformational differences in major histocompatibility com-plex-peptide complexes can result in alloreactivity.

JExp Med 179:213, 1994.

37. Weber DA, Terrell NK, Zhang Y, et al.: Requirement for peptide in alloreactive CD4+ T cell recognition of class II MHC molecules. J Immunol 154:5153, 1995.

38. Munz C, Obst R, Osen W, et al.: Alloreactivity as a source of high avidity peptide-specific human CTL. J Immunol 162:25, 1999.

39. Parham P, McQueen KL: Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 3:108, 2003.

40. Borrego F, Ulbrecht M, Weiss EH, et al.: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 187:813, 1998.

41. Colonna M, Borsellino G, Falco M, et al.: HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci USA 90:12000, 1993.

42. Moretta A, Sivori S, Vitale M, et al.: Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182:875, 1995.

43. Boyington JC, Motyka SA, Schuck P, et al.: Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 405:537, 2000.

44. Fan QR, Long EO, Wiley DC: Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2:452, 2001.

45. Gumperz JE, Litwin V, Phillips JH, et al.: The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181:1133, 1995.

46. Dohring C, Scheidegger D, Samaridis J, et al.: A human killer inhibitory receptor specific for HLA-A1,2.

J Immunol 156:3098, 1996.

47. Pende D, Biassoni R, Cantoni C, et al.: The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer.

J Exp Med 184:505, 1996.

48. Ruggeri L, Capanni M, Casucci M, et al.: Role of natural killer cell alloreactivity in HLA-mismatched hematopoi-etic stem cell transplantation. Blood 94:333, 1999.

49. Ruggeri L, Capanni M, Urbani E, et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097, 2002.

50. Leung W, Iyengar R, Turner V, et al.: Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172:644, 2004.

51. Terasaki PI: Humoral theory of transplantation. Am J Transplant 3:665, 2003.

52. Anasetti C, Amos D, Beatty PG, et al.: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320:197, 1989.

53. Mickelson EM, Petersdorf E, Anasetti C, et al.: HLA matching in hematopoietic cell transplantation. Hum Immunol 61:92, 2000.

54. Robinson J, Waller MJ, Parham P, et al.: IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 31: 311, 2003.

55. Schreuder GM, Hurley CK, Marsh SG, et al.: The HLA dictionary 2004: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Hum Immunol 66:170, 2005.

56. Duquesnoy RJ, Marrari M: HLAMatchmaker: a molecu-larly based algorithm for histocompatibility determination. II: Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol 63:353, 2002.

57. Klitz W, Maiers M, Spellman S, et al.: New HLA haplo-type frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 62:296, 2003.

58. Cao K, Hollenbach J, Shi X, et al.: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62:1009, 2001.

59. Begovich AB, McClure GR, Suraj VC, et al.: Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol 148:249, 1992.

60. Bugawan TL, Klitz W, Blair A, et al.: High-resolution HLA class I typing in the CEPH families: analysis of linkage disequilibrium among HLA loci. Tissue Antigens 56:392, 2000.

61. Pedron B, Duval M, Elbou OM, et al.: Common genomic HLA haplotypes contributing to successful donor search in unrelated hematopoietic transplantation. Bone Marrow Transplant 31:423, 2003.

62. Oudshoorn M, Cornelissen JJ, Fibbe WE, et al.: Problems and possible solutions in finding an unrelated bone marrow donor. Results of consecutive searches for 240 Dutch patients. Bone Marrow Transplant 20:1011, 1997.

63. Tron de Bouchony E, Leberre C, Dauriac C, et al.: Relevance of 10 Caucasian HLA haplotypes in searches for unrelated bone marrow donors for 100 patients from a single center. Bone Marrow Transplant 15:845, 1995.

64. Boyington JC, Brooks AG, Sun PD: Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol Rev 181:66, 2001.

65. Imanishi T, Akaza T, Kimura A, et al.: Allele and haplo-type frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T (eds.) HLA 1991. Oxford:Oxford University Press;1992: 1065.

66. Mori M, Beatty PG, Graves M, et al.: HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 64:1017, 1997.

67. Schipper RF, D'Amaro J, Bakker JT, et al.: HLA gene haplotype frequencies in bone marrow donors worldwide registries. Hum Immunol 52:54, 1997.

68. Beatty PG, Boucher KM, Mori M, et al.: Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol 61:834, 2000.

69. Mori M, Graves M, Milford EL, et al.: Computer program to predict likelihood of finding an HLA-matched donor: methodology, validation, and application. Biol Blood Marrow Transplant 2:134, 1996.

70. Beatty PG, Mori M, Milford E: Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 60:778, 1995.

71. Parham P: Filling in the blanks. Tissue Antigens 50:318, 1997.

72. Dunn PP, Turton JR, Downing J, et al.: HLA-A*24020102L in the UK blood donor population. Tissue Antigens 63: 589, 2004.

73. Pinto C, Smith AG, Larsen CE, et al.: HLA-Cw*0409N is associated with HLA-A*2301 and HLA-B*4403-carrying haplotypes. Hum Immunol 65:181, 2004.

74. Magor KE, Taylor EJ, Shen SY, et al.: Natural inactiva-tion of a common HLA allele (A*2402) has occurred on at least three separate occasions. J Immunol 158:5242, 1997.

75. Zanone-Ramseier R, Gratwohl A, Gmur J, et al.: Sequencing of two HLA-A blank alleles: implications in unrelated bone marrow donor matching. Transplantation 67:1336, 1999.

76. Szydlo R, Goldman JM, Klein JP, et al.: Results of allo-geneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15:1767, 1997.

77. Weisdorf DJ, Anasetti C, Antin JH, et al.: Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99:1971, 2002.

78. Schipper RF, D'Amaro J, Oudshoorn M: The probability of finding a suitable related donor for bone marrow transplantation in extended families. Blood 87:800, 1996.

79. Aversa F, Tabilio A, Velardi A, et al.: Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplo-type. N Engl J Med 339:1186, 1998.

80. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al.: Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89:3864, 1997.

81. Aversa F, Tabilio A, Terenzi A, et al.: Successful engraft-ment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84:3948, 1994.

82. Godder KT, Hazlett LJ, Abhyankar SH, et al.: Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome. J Clin Oncol 18:1856, 2000.

83. Drobyski WR, Klein J, Flomenberg N, et al.: Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidenti-cal family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99:806, 2002.

84. Beatty PG, Clift RA, Mickelson EM, et al.: Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313:765, 1985.

85. Ottinger HD, Ferencik S, Beelen DW, et al.: Hemato-poietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood 102:1131, 2003.

86. Anasetti C: The role of the immunogenetics laboratory in marrow transplantation. Arch Pathol Lab Med 115:288, 1991.

87. Kanda Y, Chiba S, Hirai H, et al.: Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102:1541, 2003.

88. Hasegawa W, Lipton JH, Messner HA, et al.: Influence of one human leukocyte antigen mismatch on outcome of allogeneic bone marrow transplantation from related donors. Hematology 8:27, 2003.

89. Leung WH, Turner V, Richardson SL, et al.: Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 62:399, 2001.

90. Mehta J, Singhal S, Gee AP, et al.: Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 33:389, 2004.

91. Beatty PG: Marrow transplantation using volunteer unrelated donors in a comparison of mismatched family donor transplants: a Seattle perspective. Bone Marrow Transplant 14(suppl 4):S39, 1994.

92. Giebel S, Locatelli F, Lamparelli T, et al.: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102:814, 2003.

93. Davies SM, Ruggieri L, DeFor T, et al.: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100:3825, 2002.

94. Bornhauser M, Schwerdtfeger R, Martin H, et al.: Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103:2860, 2004.

95. Gagne K, Brizard G, Gueglio B, et al.: Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 63:271, 2002.

96. Stroncek DF: Results of bone marrow transplants from unrelated donors. Transfusion 32:180, 1992.

97. Kernan NA, Bartsch G, Ash RC, et al.: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328:593, 1993.

98. Stroncek DF, Confer DL, Leitman SF: Peripheral blood progenitor cells for HPC transplants involving unrelated donors. Transfusion 40:731, 2000.

99. Rubinstein P, Carrier C, Scaradavou A, et al.: Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339:1565, 1998.

100. Gluckman E, Rocha V, Boyer-Chammard A, et al.: Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337:373, 1997.

101. Barker JN, Wagner JE: Umbilical cord blood transplantation: current practice and future innovations. Crit Rev Oncol Hematol 48:35, 2003.

102. Rocha V, Cornish J, Sievers EL, et al.: Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97:2962, 2001.

103. Rubinstein P, Stevens CE: Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. Baillieres Best Pract Res Clin Haematol 13:565, 2000.

104. Sasazuki T, Juji T, Morishima Y, et al.: Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339:1177, 1998.

105. Morishima Y, Sasazuki T, Inoko H, et al.: The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99:4200, 2002.

106. Flomenberg N, Baxter-Lowe LA, Confer D, et al.: Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood, 104:1923, 2004.

107. Petersdorf EW, Gooley TA, Anasetti C, et al.: Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92:3515, 1998.

108. Tiercy JM, Passweg J, Van Biezen A, et al.: Isolated HLA-C mismatches in unrelated donor transplantation for CML. Bone Marrow Transplant 34:249, 2004.

109. Petersdorf EW, Longton GM, Anasetti C, et al.: Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 89:1818, 1997.

110. Petersdorf EW, Anasetti C, Martin PJ, et al.: Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104:2976, 2004.

111. El Kassar N, Legouvello S, Joseph CM, et al.: High resolution HLA class I and II typing and CTLp frequency in unrelated donor transplantation: a single-institution retrospective study of 69 BMTs. Bone Marrow Transplant 27:35, 2001.

112. Petersdorf EW, Longton GM, Anasetti C, et al.: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 86:1606, 1995.

113. Petersdorf EW, Kollman C, Hurley CK, et al.: Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 98:2922, 2001.

114. Devergie A, Apperley JF, Labopin M, et al.: European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:11, 1997.

115. Gajewski J, Gjertson D, Cecka M, et al.: The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 3:76, 1997.

116. Petersdorf EW, Longton GM, Anasetti C, et al.: Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 93:15358, 1996.

117. Schaffer M, Aldener-Cannava A, Remberger M, et al.: Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 62:243, 2003.

118. Varney MD, Lester S, McCluskey J, et al.: Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. Hum Immunol 60:532, 1999.

119. Loiseau P, Esperou H, Busson M, et al.: DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation. Bone Marrow Transplant 30:497, 2002.

120. Shaw BE, Potter MN, Mayor NP, et al.: The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation. Bone Marrow Transplant 31:1001, 2003.

121. Petersdorf EW, Gooley T, Malkki M, et al.: The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol 112: 988, 2001.

122. Petersdorf EW, Smith AG, Mickelson EM, et al.: The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. Blood 81:1923, 1993.

123. Nagler A, Brautbar C, Slavin S, et al.: Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity. Bone Marrow Transplant 18:891, 1996.

124. Ottenhoff TH, Elferink DG, Termijtelen A, et al.: HLA class II restriction repertoire of antigen-specific T cells. II: Evidence for a new restriction determinant associated with DRw52 and LB-Q1. Hum Immunol 13:117, 1985.

125. Berle EJ Jr, Thorsby E: Both DR and MT class II HLA molecules may restrict proliferative T-lymphocyte responses to antigen. Scand J Immunol 16:543, 1982.

126. Beatty PG, Anasetti C, Hansen JA, et al.: Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 81:249, 1993.

127. Davies SM, Shu XO, Blazar BR, et al.: Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood 86:1636,

0 0

Post a comment